According to Genomeweb, Illumina had 66% of the market in 2012:
Roche's share was 8% at this point.
I think you may have been a bit misled on their market penetration post PGM and post-MiSeq
-
Why is any technology killed off? It's been superseded - either on price or performance or both.
According to Genomeweb, Illumina had 66% of the market in 2012:
Roche's share was 8% at this point.
I think you may have been a bit misled on their market penetration post PGM and post-MiSeq -
{Discussion}Roche stop supporting the 454 platform by mid-2016
Hi, I am a graduate student and I have just heard Roche stop supporting the 454 pyrosequencing platform by 2016. Our university has to buy another Next-gen sequencing platform.
I was surprised. Does anyone know what happened? Two year ago, I think 454 pyrosequencing occupied >50% market. I don't think this is about business. Also, lots of publications use pyrosequencing
Are they gonna develop new sequencing technologies? Is pyrosequencing a technological dead end? Is Illumina a good choice?
Ben
-
Non-coding RNAs (ncRNAs) do not code for proteins but play important roles in numerous cellular processes including gene silencing, developmental pathways, and more. There are numerous types including microRNA (miRNA), long ncRNA (lncRNA), circular RNA (circRNA), and more. In this article, we discuss innovative ncRNA research and explore recent technological advancements that improve the study of ncRNAs.
Nobel Prize for MicroRNA Discovery
This week,...10-07-2024, 08:07 AM -
Metagenomics has improved the way researchers study microorganisms across diverse environments. Historically, studying microorganisms relied on culturing them in the lab, a method that limits the investigation of many species since most are unculturable1. Metagenomics overcomes these issues by allowing the study of microorganisms regardless of their ability to be cultured or the environments they inhabit. Over time, the field has evolved, especially with the advent...09-23-2024, 06:35 AM
Leave a comment: